Blog Posts

RWC-340B Opposes and Hemophilia Alliance Questions PhRMA and NACHC’s Push to Remake 340B

RWC-340B Hemophilia Alliance
RWC-340B rejected and Hemophilia Alliance criticized PhRMA and NACHC's joint plan to restructure the 340B program.

Ryan White Clinics for 340B Access has announced it opposes the drug industry’s joint plan with community health centers to restructure the 340B program, saying it will increase manufacturers’ “already astronomical profits at the expense of safety net

Read More »

340B Expected to Be Addressed During U.S. House Hearing Today

E&C
The 340B program is expected to come up today during a U.S. House Energy & Commerce health subcommittee hearing.

Lawmakers and heath care policy experts are expected to discuss the 340B program this afternoon during a U.S. House Energy & Commerce health subcommittee hearing.

The hearing on lowering health care costs through more price transparency and

Read More »

AHF: Addressing Syphilis Disparities in Franklin County, OH

SPONSORED CONTENT

In 1999, the Centers for Disease Control and Prevention (CDC) launched the National Campaign to Eliminate Syphilis from the United States. The CDC updated its ambitious plan in 2006 and aimed to reduce rates of primary and secondary syphilis to less than 2.2 cases per 100,000 population, congenital syphilis

Read More »

N.Y. State Health Centers Sue to Stop April 1 Shift of Medicaid Managed Care Drug Benefits to Fee for Service

Evergreen Health
Buffalo, N.Y.-based health center Evergreen Health and Harlem, N.Y.-based health health center Heritage Health and Housing asked a state court to halt Saturday's scheduled transfer of Medicaid drug benefits from managed care to fee for service.

The clock is ticking down in New York state to the scheduled April 1 transfer of Medicaid managed care drug benefits to Medicaid fee for service—a move that 340B safety net providers say would result in financial disaster.

Read More »

HRSA Posts Two Drug Manufacturer Notices to 340B Entities

Vtama
Dermavant Sciences is giving refunds to health care providers that paid above the 340B ceiling price for Vtama, a treatment for plaque psoriasis.

Biopharmaceutical company Dermavant Sciences is giving refunds to health care providers that paid above the 340B ceiling price for Vtama, a non-steroidal cream to treat plaque psoriasis.

The U.S. Health Resources and Services Administration posted Dermavant’s notice to

Read More »

Confidential Document Fleshes Out ASAP 340B’s Reform Objectives

Confidential
PhRMA has written an eight-page document that elaborates on its principles for 340B program reform.

A confidential document composed by Pharmaceutical Research and Manufacturers of America in connection with its 340B program reform initiative with the National Association of Community Health Centers fleshes out a “coalition” vision of the 10-point reform plan that

Read More »

340B Hospitals Say Pharma’s Contract Pharmacy Policies Are Costing Them “Billions of Dollars”

340b Health
340B Health says, "For just the first five of the 21 drug companies for which there is a full year of data post-restrictions, the 340B savings for hospitals decreased by an estimated $1.1 billion from 2020 to 2021."

Hospitals’ 340B savings for the first five of the 21 companies to impose conditions on 340B pricing when providers use contract pharmacies decreased by an estimated $1.1 billion from 2020 to 2021, hospital group 340B Health said in

Read More »

Four Best Practices for Running Mock Audits

SPONSORED CONTENT

With new leadership in Congress, the drumbeat for greater scrutiny of 340B will grow. To date, news outlets from The New York Times to The Wall Street Journal have quoted former government officials and pundits who’ve called for more oversight of the 340B

Read More »

Sean Dickson, Known for 340B Research, Takes Senior Post at Health Insurance Association

Sean Dickson
Sean Dickson, a drug policy expert who has published frequently cited research on 340B, has gone to work for the health insurance industry.

Sean Dickson, a drug policy expert who has published frequently cited research on the 340B program and advised both health care providers and drug manufacturers on 340B compliance, has gone to work for the health insurance industry.

Dickson,

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer